Wed Jun 9 12:39:43 2021
(*5e05c158*):: An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program +public!
military’s mandatory vaccination program and heightened concerns regarding the use of anthrax as an agent of terrorism or warfare, two key reports have been released in recent years regarding the anthrax *vaccine*.
• Bates SG. 2001. Written statement. Institute of Medicine Joint Meeting of the Committee to Assess the Safety and Efficacy of the Anthrax *Vaccine* and the Committee to Review the CDC Anthrax *Vaccine* Safety and Efficacy Research Program, Meeting III, Washington, D.C.
• FDA. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register 67(105):37988–37998. [
• IOM (Institute of Medicine). 1994. a. Stratton KR, editor; , Howe CJ, editor; , Johnston RB Jr, editor. , eds. _Adverse Events Associated with_ _Childhood *Vaccines*: Evidence Bearing on Causality_. Washington, D.C.: National Academy Press.
• IOM. 1994. b. Stratton KR, editor; , Howe CJ, editor; , Johnston RB Jr, editor. , eds. _Research Strategies for Assessing Adverse Events Associ_ _ated with *Vaccines*: a Workshop Summary_. Washington, D.C.: National Academy Press.
National Childhood *Vaccine* Injury Act of 1986. P. L. No. 99-660 (1986).
— New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule – PubMed
— The Food and Drug Administration (FDA) is amending its new drug and biological product regulations to allow appropriate studies in animals in certain cases to provide substantial evidence of the effectiveness of new drug and biological products used to reduce or prevent the toxicity of chemical, bio …
